ES2687979T3 - Métodos de diagnóstico de la enfermedad valvular crónica - Google Patents

Métodos de diagnóstico de la enfermedad valvular crónica Download PDF

Info

Publication number
ES2687979T3
ES2687979T3 ES13729199.3T ES13729199T ES2687979T3 ES 2687979 T3 ES2687979 T3 ES 2687979T3 ES 13729199 T ES13729199 T ES 13729199T ES 2687979 T3 ES2687979 T3 ES 2687979T3
Authority
ES
Spain
Prior art keywords
animal
sample
metabolites
amount
valvular disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13729199.3T
Other languages
English (en)
Spanish (es)
Inventor
Qinghong LI
Dorothy P. Laflamme
Steven S. Hannah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Application granted granted Critical
Publication of ES2687979T3 publication Critical patent/ES2687979T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/491—Blood by separating the blood components
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/16—Phosphorus containing
    • Y10T436/163333—Organic [e.g., chemical warfare agents, insecticides, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/20—Oxygen containing
    • Y10T436/200833—Carbonyl, ether, aldehyde or ketone containing
    • Y10T436/201666—Carboxylic acid

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Endocrinology (AREA)
  • Ecology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
ES13729199.3T 2012-06-05 2013-06-04 Métodos de diagnóstico de la enfermedad valvular crónica Active ES2687979T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261655704P 2012-06-05 2012-06-05
US201261655704P 2012-06-05
PCT/US2013/044008 WO2013184628A1 (en) 2012-06-05 2013-06-04 Methods for diagnosing chronic valvular disease

Publications (1)

Publication Number Publication Date
ES2687979T3 true ES2687979T3 (es) 2018-10-30

Family

ID=48626663

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13729199.3T Active ES2687979T3 (es) 2012-06-05 2013-06-04 Métodos de diagnóstico de la enfermedad valvular crónica

Country Status (12)

Country Link
US (1) US20150153353A1 (https=)
EP (1) EP2856170B1 (https=)
JP (1) JP6174689B2 (https=)
CN (1) CN104364658B (https=)
AU (1) AU2013271879B2 (https=)
BR (1) BR112014030243B1 (https=)
CA (1) CA2875331C (https=)
ES (1) ES2687979T3 (https=)
IN (1) IN2014DN10127A (https=)
MX (1) MX358561B (https=)
RU (1) RU2667634C2 (https=)
WO (1) WO2013184628A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10184932B2 (en) * 2015-12-07 2019-01-22 Zora Biosciences Oy Use of ceramides and LPLs in diagnosing CVD

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257943A1 (en) * 2005-01-25 2006-11-16 Cis Biotech, Inc. Ischemic biomarkers and their use to predict adverse neurological events from surgery
MX2010000414A (es) * 2007-07-17 2010-04-01 Metabolon Inc Biomarcadores para prediabetes, enfermedades cardiovasculares y otros trastornos relacionados con sindrome metabolico, y metodos de uso de los mismos.
JP5654352B2 (ja) * 2007-11-09 2015-01-14 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ｍｉＲ−１５ファミリーのマイクロＲＮＡによる心筋細胞生存及び心臓修復の調節
EP2283358B1 (en) * 2008-04-29 2015-04-22 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
DK2271933T3 (da) * 2008-05-07 2013-04-02 Univ Strathclyde System og fremgangsmåde til cellekarakterisering
SG172855A1 (en) * 2009-01-29 2011-08-29 Abbott Lab Il-1 binding proteins
EP2596134B1 (en) * 2010-07-23 2020-04-08 President and Fellows of Harvard College Methods of detecting diseases or conditions using phagocytic cells

Also Published As

Publication number Publication date
WO2013184628A1 (en) 2013-12-12
RU2014153109A (ru) 2016-08-10
EP2856170B1 (en) 2018-07-25
CN104364658B (zh) 2017-06-30
CA2875331A1 (en) 2013-12-12
MX358561B (es) 2018-08-24
RU2667634C2 (ru) 2018-09-21
MX2014014791A (es) 2015-02-24
BR112014030243A2 (pt) 2017-06-27
AU2013271879A1 (en) 2014-12-18
US20150153353A1 (en) 2015-06-04
BR112014030243B1 (pt) 2022-07-05
JP6174689B2 (ja) 2017-08-02
CA2875331C (en) 2022-11-29
JP2015524066A (ja) 2015-08-20
IN2014DN10127A (https=) 2015-08-21
CN104364658A (zh) 2015-02-18
EP2856170A1 (en) 2015-04-08
AU2013271879B2 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
Wu et al. Metabolomic investigation of gastric cancer tissue using gas chromatography/mass spectrometry
Snowden et al. Application of metabolomics approaches to the study of respiratory diseases
AU2014265669B2 (en) Biomarkers related to kidney function and methods using the same
JP6763770B2 (ja) 自閉症スペクトラム障害のバイオマーカー
US20200191768A1 (en) Biomarker for diagnosing depression and use of biomarker
ES2927921T3 (es) Métodos que utilizan paneles de metabolitos para el diagnóstico y diferenciación de la encefalopatía neonatal
García-Fontana et al. Metabolomic profile related to cardiovascular disease in patients with type 2 diabetes mellitus: a pilot study
Hanna et al. Urinary metabolomic markers of aminoglycoside nephrotoxicity in newborn rats
Bu et al. Metabolomics: a revolution for novel cancer marker identification
US10533989B2 (en) Metabolomics in pneumonia and sepsis
Kim et al. Differential levels of L-homocysteic acid and lysophosphatidylcholine (16: 0) in sera of patients with ovarian cancer
Patel et al. Improved detection and precise relative quantification of the urinary cancer metabolite biomarkers–Creatine riboside, creatinine riboside, creatine and creatinine by UPLC-ESI-MS/MS: Application to the NCI-Maryland cohort population controls and lung cancer cases
US20240352542A1 (en) Means and methods for diagnosing a viral infection or a disease associated therewith
Djukovic et al. Colorectal cancer detection using targeted LC-MS metabolic profiling
ES2687979T3 (es) Métodos de diagnóstico de la enfermedad valvular crónica
KR20220162918A (ko) 아실카르니틴 대사체를 포함하는 구강암 진단용 바이오마커 조성물
JP7838771B2 (ja) 胆道がん検査方法
WO2015183917A2 (en) Metabolic biomarkers for memory loss
López Bascón Analytical strategies to improve qualitative and quantitative determination in metabolomics by mass spectrometry
Banoei Metabolomics Study of the Diagnosis and Prognosis of Severe Traumatic Brain Injury (sTBI)
US20200232995A1 (en) Measurement of protein molecular flux rates by quantifying isotopologue abundances in immonium ion using high resolution mass spectrometry
de Fátima Cobre et al. Multi-omics data analysis of COVID-19 patients from Italy, China, Spain and France reveals new biomarkers for early diagnosis and prognosis of SARS-CoV-2 infection
Servià Goixart et al. A prospective pilot study using metabolomics discloses specific fatty acid, catecholamine and tryptophan metabolic pathways as possible predictors for a negative outcome after severe trauma
Pértega-Gomes et al. Innovation in Metabonomics to Improve Personalized Health Care
Ch Metabolomics in health and disease biology